A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

Inclusion Criteria

• Inclusion Criteria Phase 1b (all arms): - Solid tumor, advanced or metastatic, progressed on standard treatment participants in Arm B must have either triple negative breast cancer OR urothelial carcinoma OR ovarian cancer OR have a solid tumor with a deleterious mutation in BRCA1, BRCA2, PALB2, RAD51C or RAD51D - Measurable disease per RECIST v1.1 - Adequate organ function - Eastern Cooperative Oncology Group (ECOG) 0 or 1 - Tumor tissue for genomic analysis Exclusion Criteria Phase 1b (all arms): - Known history of myelodysplastic syndrome (MDS) - Symptomatic and/or untreated central nervous system (CNS) metastases Inclusion Criteria Phase 2 (all arms): - Histologically or cytologically confirmed solid tumor, previously treated and measurable per RECIST v1.1, as follows: - Arm A: ovarian cancer with gBRCAwt disease, either platinum-sensitive OR platinum-resistant - Arm B: Metastatic triple negative breast cancer OR advanced/ metastatic urothelial carcinoma OR relapsed ovarian cancer - At least 1 prior line of standard therapy for advanced disease - Adequate organ function - ECOG 0 or 1 - Tumor tissue for genomic analysis Exclusion Criteria Phase 2 (all arms): - Prior poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor treatment allowed for participants with ovarian cancer - Known history of MDS - Symptomatic and/or untreated CNS metastases